Journal article · 2019 · Open access
Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial
The Lancet, 394(10202), 929–938 · Published 18 July 2019 · DOI 10.1016/s0140-6736(19)31285-1
In brief
“Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial” is a 2019 journal article by Walter R. J. Taylor and 44 co-authors, published in The Lancet. OpenAlex counts 207 citations as of 20 November 2026, which puts it in the top 4% of works published in 2019 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet.
- Citations
- 207
- Most cited in
- 2021 (42)
- Field-weighted impact
- 19.72
- References
- 29
- Authors
- 45
Abstract
BACKGROUND: Primaquine is the only widely used drug that prevents Plasmodium vivax malaria relapses, but adherence to the standard 14-day regimen is poor. We aimed to assess the efficacy of a shorter course (7 days) of primaquine for radical cure of vivax malaria. METHODS: We did a randomised, double-blind, placebo-controlled, non-inferiority trial in eight health-care clinics (two each in Afghanistan, Ethiopia, Indonesia, and Vietnam). Patients (aged ≥6 months) with normal glucose-6-phosphate dehydrogenase (G6PD) and presenting with uncomplicated vivax malaria were enrolled. Patients were given standard blood schizontocidal treatment and randomly assigned (2:2:1) to receive 7 days of supervised primaquine (1·0 mg/kg per day), 14 days of supervised primaquine (0·5 mg/kg per day), or placebo. The primary endpoint was the incidence rate of symptomatic P vivax parasitaemia during the 12-month follow-up period, assessed in the intention-to-treat population. A margin of 0·07 recurrences per person-year was used to establish non-inferiority of the 7-day regimen compared with the 14-day regimen. This trial is registered at ClinicalTrials.gov (NCT01814683). FINDINGS: Between July 20, 2014, and Nov 25, 2017, 2336 patients were enrolled. The incidence rate of symptomatic recurrent P vivax malaria was 0·18 (95% CI 0·15 to 0·21) recurrences per person-year for 935 patients in the 7-day primaquine group and 0·16 (0·13 to 0·18) for 937 patients in the 14-day primaquine group, a difference of 0·02 (-0·02 to 0·05, p=0·3405). The incidence rate for 464 patients in the placebo group was 0·96 (95% CI 0·83 to 1·08) recurrences per person-year. Potentially drug-related serious adverse events within 42 days of starting treatment were reported in nine (1·0%) of 935 patients in the 7-day group, one (0·1%) of 937 in the 14-day group and none of 464 in the control arm. Four of the serious adverse events were significant haemolysis (three in the 7-day group and one in the 14-day group). INTERPRETATION: In patients with normal G6PD, 7-day primaquine was well tolerated and non-inferior to 14-day primaquine. The short-course regimen might improve adherence and therefore the effectiveness of primaquine for radical cure of P vivax malaria. FUNDING: UK Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust through the Joint Global Health Trials Scheme (MR/K007424/1) and the Bill & Melinda Gates Foundation (OPP1054404).
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Taylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Châu, N. H., Cheah, P. Y., Dong, L. T., Dhorda, M., Degaga, T. S., Devine, A., Ekawati, L. L., Fahmi, F., Hailu, A., Hasanzai, M. A., Hien, T. T., . . . Price, R. N. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. The Lancet, 394(10202), 929–938. https://doi.org/10.1016/s0140-6736(19)31285-1
MLA 9
Taylor, Walter R. J., et al. “Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.” The Lancet, vol. 394, no. 10202, 2019, pp. 929–938. https://doi.org/10.1016/s0140-6736(19)31285-1.
Chicago
Taylor, Walter R. J., Kamala Thriemer, Lorenz von Seidlein, Prayoon Yuentrakul, Thanawat Assawariyathipat, Ashenafi Assefa, Sarah Auburn, et al. 2019. “Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial.” The Lancet 394 (10202): 929–938. https://doi.org/10.1016/s0140-6736(19)31285-1.
Harvard
Taylor, W. R. J. et al. (2019) ‘Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial’, The Lancet, 394(10202), pp. 929–938. doi:10.1016/s0140-6736(19)31285-1.
IEEE
W. R. J. Taylor et al., “Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial,” The Lancet, vol. 394, no. 10202, pp. 929–938, 2019, doi: 10.1016/s0140-6736(19)31285-1.
BibTeX
@article{taylor2019short,
title = {{Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial}},
author = {Taylor, Walter R. J. and Thriemer, Kamala and von Seidlein, Lorenz and Yuentrakul, Prayoon and Assawariyathipat, Thanawat and Assefa, Ashenafi and Auburn, Sarah and Chand, Krisin and Châu, Nguyễn Hoàng and Cheah, Phaik Yeong and Dong, Le Thanh and Dhorda, Mehul and Degaga, Tamiru Shibiru and Devine, Angela and Ekawati, Lenny Lia and Fahmi, Fahmi and Hailu, Asrat and Hasanzai, Mohammad Anwar and Hien, Tran Tinh and Khu, Htee and Ley, Benedikt and Lubell, Yoel and Marfurt, Jutta and Mohammad, Hussein and Moore, Kerryn A. and Naddim, Mohammad Nader and Pasaribu, Ayodhia Pitaloka and Pasaribu, Syahril and Promnarate, Cholrawee and Awab, Ghulam Rahim and others},
journal = {The Lancet},
year = {2019},
volume = {394},
number = {10202},
pages = {929--938},
doi = {10.1016/s0140-6736(19)31285-1},
url = {https://doi.org/10.1016/s0140-6736(19)31285-1}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2019 | 4 | |
| 2020 | 24 | |
| 2021 | 42 | |
| 2022 | 30 | |
| 2023 | 32 | |
| 2024 | 23 | |
| 2025 | 27 | |
| 2026 | 25 |
Its field-weighted citation impact is 19.72: it has been cited 19.72 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- primaquine
- Plasmodium vivax
- radical cure
- non-inferiority
- glucose-6-phosphate dehydrogenase
- malaria treatment
- drug safety
- adverse events
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Taylor, W. R. J., Thriemer, K., von Seidlein, L., Yuentrakul, P., Assawariyathipat, T., Assefa, A., Auburn, S., Chand, K., Châu, N. H., Cheah, P. Y., Dong, L. T., Dhorda, M., Degaga, T. S., Devine, A., Ekawati, L. L., Fahmi, F., Hailu, A., Hasanzai, M. A., Hien, T. T., . . . Price, R. N. (2019). Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. The Lancet, 394(10202), 929–938. https://doi.org/10.1016/s0140-6736(19)31285-1
How many times has this paper been cited?
207 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at The Lancet: sign in and open the PDF from this page.
Who wrote this paper?
Walter R. J. Taylor, Kamala Thriemer, Lorenz von Seidlein, Prayoon Yuentrakul, Thanawat Assawariyathipat, Ashenafi Assefa, Sarah Auburn, Krisin Chand, Nguyễn Hoàng Châu, Phaik Yeong Cheah, Le Thanh Dong, Mehul Dhorda and 33 more.
What is the DOI of this paper?
10.1016/s0140-6736(19)31285-1, permanently at https://doi.org/10.1016/s0140-6736(19)31285-1. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.